Business
Temu Marketplace Stock Photo Illustrations
(Nikos Pekiaridis/Getty Images)

Shein and Temu start hiking prices as tariffs and shipping crackdown take effect

China’s fast-fashion giants are adjusting their price tags as trade tensions threaten their ultracheap empire.

Shein and PDD Holdings Temu have reportedly started hiking prices as a double whammy of rising tariffs and the end of a major import tax exemption threaten their bottom line.

Both companies have warned shoppers that price tags would go up on April 25 — and users are already spotting sticker shock across social media and Reddit.

The squeeze comes after President Trump announced new plans to jack up fees on small parcel shipments, shutting down the decades-old “de minimis” exemption that helped Chinese marketplaces flood US homes with rock-bottom goods. While Shein and Temu have downplayed the role of the exemption in their bargain-bin pricing, the combo of soaring tariffs — now up to 145% on some goods — and new import rules could change that story fast.

It’s already leaving a mark: Temu tumbled from its usual top-five ranking to No. 64 among free apps in Apple’s US App Store last week, just days after it suddenly yanked its Google Shopping ads. It’s a stunning fall from grace for a platform that was America’s most downloaded app just months ago.

The timing could be especially tricky for Shein, which has been prepping for a splashy IPO in the UK — but still counts the US as one of its most critical markets. The impact on American consumers can’t be overstated: a recent survey found that nearly 70% of US consumers have bought from Chinese marketplaces including Shein, Temu, AliExpress, or TikTok Shop in the past year — and nearly half shopped across more than one.

More Business

See all Business
Strive Pharmacy recently broke ground on a new facility in Mesa, Arizona. (Strive Pharmacy)

Before Hims’ GLP-1 pill fallout, its pharmacy partner was already drawing scrutiny from state regulators

Strive has already been probed over the timing of its GLP-1 compounding. Now, Arizona regulators are looking into complaints about ketamine misuse and improper distribution of prescription drugs.

business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.